Investment Centers of America Inc. Increases Position in Becton, Dickinson and Company (BDX)

Investment Centers of America Inc. increased its stake in shares of Becton, Dickinson and Company (NYSE:BDX) by 15.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,534 shares of the medical instruments supplier’s stock after acquiring an additional 612 shares during the quarter. Investment Centers of America Inc.’s holdings in Becton, Dickinson and were worth $891,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in BDX. Waldron LP bought a new position in Becton, Dickinson and during the first quarter worth $383,000. Goelzer Investment Management Inc. bought a new position in Becton, Dickinson and during the first quarter worth $237,000. Thomaspartners Inc. increased its position in Becton, Dickinson and by 6.9% during the first quarter. Thomaspartners Inc. now owns 1,134,326 shares of the medical instruments supplier’s stock worth $208,081,000 after acquiring an additional 73,683 shares during the period. Karp Capital Management Corp bought a new position in Becton, Dickinson and during the first quarter worth $27,239,000. Finally, FormulaFolio Investments LLC bought a new position in Becton, Dickinson and during the first quarter worth $205,000. 87.12% of the stock is currently owned by institutional investors and hedge funds.

In related news, insider Thomas E. Polen, Jr. sold 5,971 shares of the firm’s stock in a transaction on Wednesday, August 9th. The stock was sold at an average price of $197.41, for a total value of $1,178,735.11. Following the transaction, the insider now owns 12,861 shares in the company, valued at $2,538,890.01. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Gary M. Cohen sold 15,512 shares of the firm’s stock in a transaction on Monday, September 11th. The stock was sold at an average price of $203.77, for a total value of $3,160,880.24. Following the completion of the transaction, the insider now owns 95,781 shares in the company, valued at approximately $19,517,294.37. The disclosure for this sale can be found here. Insiders sold 75,904 shares of company stock worth $15,242,688 in the last 90 days. 1.40% of the stock is owned by company insiders.

A number of equities analysts recently issued reports on BDX shares. Raymond James Financial, Inc. raised shares of Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and dropped their target price for the stock from $210.00 to $180.00 in a research report on Friday, June 30th. Piper Jaffray Companies reaffirmed a “buy” rating and set a $213.00 target price on shares of Becton, Dickinson and in a research report on Tuesday, September 12th. Bank of America Corporation reaffirmed a “buy” rating and set a $225.00 target price (up previously from $200.00) on shares of Becton, Dickinson and in a research report on Friday, July 21st. Zacks Investment Research raised shares of Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $225.00 target price on the stock in a research report on Monday, July 17th. Finally, Wells Fargo & Company started coverage on shares of Becton, Dickinson and in a research report on Friday, September 22nd. They set an “outperform” rating and a $225.00 target price on the stock. One analyst has rated the stock with a sell rating, four have issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $200.93.

TRADEMARK VIOLATION NOTICE: This piece was first published by Markets Daily and is the sole property of of Markets Daily. If you are reading this piece on another domain, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The legal version of this piece can be accessed at https://www.themarketsdaily.com/2017/10/13/investment-centers-of-america-inc-increases-position-in-becton-dickinson-and-company-bdx.html.

Becton, Dickinson and (NYSE:BDX) last issued its quarterly earnings results on Thursday, August 3rd. The medical instruments supplier reported $2.46 EPS for the quarter, topping the Zacks’ consensus estimate of $2.44 by $0.02. Becton, Dickinson and had a return on equity of 22.53% and a net margin of 6.25%. The company had revenue of $3.04 billion for the quarter, compared to analysts’ expectations of $3.06 billion. During the same quarter last year, the business earned $2.35 earnings per share. Becton, Dickinson and’s revenue was down 5.1% on a year-over-year basis.

The business also recently declared a quarterly dividend, which was paid on Friday, September 29th. Investors of record on Friday, September 8th were given a $0.73 dividend. This represents a $2.92 dividend on an annualized basis and a dividend yield of 1.47%. The ex-dividend date was Thursday, September 7th. Becton, Dickinson and’s payout ratio is currently 83.43%.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.

Institutional Ownership by Quarter for Becton, Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply